Journal article

Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma.

Michael Dickinson, Javier Briones, Alex F Herrera, Eva González-Barca, Nilanjan Ghosh, Raul Cordoba, Sarah C Rutherford, Eirini Bournazou, Emily Labriola-Tompkins, Izolda Franjkovic, Evelyne Chesne, Jurriaan Brouwer-Visser, Katharina Lechner, Barbara Brennan, Eveline Nüesch, Mark DeMario, Dominik Rüttinger, Martin Kornacker, Martin Hutchings

Blood Adv | Published : 2021

Abstract

Bromodomain and extraterminal (BET) proteins are transcriptional activators for multiple oncogenic processes in diffuse large B-cell lymphoma (DLBCL), including MYC, BCL2, E2F, and toll-like receptor signaling. We report results of a phase 1b dose-escalation study of the novel, subcutaneous BET inhibitor RO6870810 (RO) combined with the BCL-2 inhibitor venetoclax, and rituximab, in recurrent/refractory DLBCL. RO was delivered for 14 days of a 21-day cycle, whereas venetoclax was delivered continuously. A 3 + 3 escalation design was used to determine the safety of the RO+venetoclax doublet; rituximab was added in later cohorts. Thirty-nine patients were treated with a median of 2.8 cycles (ra..

View full abstract